AKRO

$0.00

(

+0.00%

)
Quote details

stock

Akero Therapeutics Inc

NASDAQ | AKRO

47.74

USD

+$0.00

(

+0.00%

)

At Close (As of Sep 26, 2025)

$3.70B

Market Cap

-

P/E Ratio

-3.81

EPS

$58.40

52 Week High

$21.34

52 Week Low

HEALTHCARE

Sector

AKRO Chart

Recent Chart
Price Action

AKRO Technicals

Tags:

AKRO Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$18K
Total Revenue $0
Cost Of Revenue $18K
Costof Goods And Services Sold $18K
Operating Income -$285M
Selling General And Administrative $38M
Research And Development $247M
Operating Expenses $285M
Investment Income Net -
Net Interest Income $33M
Interest Income $38M
Interest Expense $4.7M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization -$29M
Income Before Tax -$252M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$252M
Comprehensive Income Net Of Tax -
Ebit -$257M
Ebitda -$285M
Net Income -$252M

Revenue & Profitability

Earnings Performance

AKRO Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $826M
Total Current Assets $770M
Cash And Cash Equivalents At Carrying Value $340M
Cash And Short Term Investments $340M
Inventory -
Current Net Receivables -
Total Non Current Assets $56M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments $55M
Short Term Investments $403M
Other Current Assets $27M
Other Non Current Assets -
Total Liabilities $76M
Total Current Liabilities $40M
Current Accounts Payable $9M
Deferred Revenue -
Current Debt -
Short Term Debt $291K
Total Non Current Liabilities $36M
Capital Lease Obligations $1.2M
Long Term Debt $35M
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $36M
Other Current Liabilities $30M
Other Non Current Liabilities $194K
Total Shareholder Equity $750M
Treasury Stock -
Retained Earnings -$826M
Common Stock $7K
Common Stock Shares Outstanding $67M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$230M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $18K
Capital Expenditures $999K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$110M
Cashflow From Financing $446M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity $464K
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$252M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$18K
Total Revenue $0
Cost Of Revenue $18K
Costof Goods And Services Sold $18K
Operating Income -$285M
Selling General And Administrative $38M
Research And Development $247M
Operating Expenses $285M
Investment Income Net -
Net Interest Income $33M
Interest Income $38M
Interest Expense $4.7M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization -$29M
Income Before Tax -$252M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$252M
Comprehensive Income Net Of Tax -
Ebit -$257M
Ebitda -$285M
Net Income -$252M

AKRO News

AKRO Profile

Akero Therapeutics Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Akero Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for the treatment of nonalcoholic steatohepatitis (NASH), a significant liver disease linked to cardiometabolic health. With its headquarters in South San Francisco, California, Akero is leveraging its proprietary drug development platform to restore metabolic balance and enhance patient outcomes. The company is at the forefront of advancing solutions that address the evolving needs of patients suffering from metabolic disorders.

DVLT
+30.57%
$1.09
INTC
+4.44%
$35.50
GPUS
+19.56%
$0.45
CGBS
-39.47%
$0.03
DFLI
+38.45%
$0.52
YAAS
-31.07%
$0.06
SNAP
-0.72%
$8.27
NEHC
+33.33%
$1.84
NUAI
+33.33%
$1.84
CJET
+10.63%
$0.17
NVDA
+0.28%
$178.19
F
+3.35%
$12.01
PSTV
+9.60%
$0.61
DNN
-3.14%
$2.77
APLT
+121.34%
$1.24
TSLA
+4.01%
$440.40
RGTI
-2.86%
$31.18
BIAF
+55.13%
$5.29
PLUG
+0.42%
$2.37
CIFR
-1.62%
$11.47
NIO
-5.75%
$7.04
ADAP
+15.74%
$0.14
WOK
-5.22%
$0.08
AAL
-0.70%
$11.31
RIG
+0.94%
$3.19
IONZ
+5.83%
$4.34
TPIC
-45.91%
$0.12
AXDX
-61.36%
$0.03
MRM
+102.75%
$2.94
QBTS
+1.59%
$26.76
VALE
-1.74%
$10.70
IREN
-9.57%
$41.86
BTG
+1.44%
$4.92
BLMZ
+12.51%
$0.20
QUBT
-2.11%
$20.14
MARA
+0.37%
$16.13
KVUE
+1.54%
$16.42
RIOT
+5.67%
$17.69
KDLY
+7.69%
$1.26
ATCH
-4.25%
$0.79
AAPL
-0.54%
$255.46
SOUN
-2.50%
$15.94
PLTR
-0.86%
$177.57
BITF
-5.22%
$2.54
BBD
+0.91%
$3.30
TLRY
-3.36%
$1.14
WBD
-1.36%
$19.51
AMZN
+0.74%
$219.78
FCX
+1.16%
$35.75
BURU
-10.14%
$0.12
BMNR
+1.87%
$50.50
IXHL
-0.01%
$0.59
ETHD
-6.19%
$3.94
RMBL
+60.50%
$3.21
RXRX
+1.94%
$4.72
SHOT
+12.24%
$0.28
RR
+2.68%
$4.20
GRAB
-2.24%
$6.11
ADD
-25.47%
$0.05
RAYA
-3.15%
$0.04
RIVN
-0.95%
$15.59
SOFI
-0.49%
$27.98
ONDS
-1.16%
$7.66
BULL
+3.55%
$15.16
CVE
+0.39%
$17.77
CLSK
-5.26%
$12.96
SRM
+53.27%
$10.30
ACHR
-0.53%
$9.27
PFE
+0.67%
$23.76
IONQ
-3.09%
$67.28
BB
+6.66%
$4.96
JOBY
+1.57%
$16.11
NOK
-0.42%
$4.66
AMD
-1.12%
$159.46
CRWV
-4.98%
$120.34
CLF
+2.48%
$12.37
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
BTE
+2.43%
$2.52
QS
+1.28%
$12.66
WLGS
-5.57%
$0.04
HIMS
+6.43%
$58.40
AQMS
+48.37%
$7.30
ABEV
0.00%
$2.29
MRVL
-0.76%
$83.17
ETWO
0.00%
$3.30
ORCL
-2.70%
$283.45
HBAN
+0.57%
$17.42
HOOD
-0.70%
$121.78
AG
+4.02%
$12.14
AIIO
-15.63%
$2.04
NWTN
-15.63%
$2.04
SDM
-86.40%
$1.85
T
+0.03%
$28.31
OKLO
-7.21%
$110.53
ITUB
+0.55%
$7.24
MU
+0.28%
$157.27
PCG
+3.67%
$14.97
PR
-0.07%
$13.68
AFMD
-34.94%
$0.18
DVLT
+30.57%
$1.09
INTC
+4.44%
$35.50
GPUS
+19.56%
$0.45
CGBS
-39.47%
$0.03
DFLI
+38.45%
$0.52
YAAS
-31.07%
$0.06
SNAP
-0.72%
$8.27
NEHC
+33.33%
$1.84
NUAI
+33.33%
$1.84
CJET
+10.63%
$0.17
NVDA
+0.28%
$178.19
F
+3.35%
$12.01
PSTV
+9.60%
$0.61
DNN
-3.14%
$2.77
APLT
+121.34%
$1.24
TSLA
+4.01%
$440.40
RGTI
-2.86%
$31.18
BIAF
+55.13%
$5.29
PLUG
+0.42%
$2.37
CIFR
-1.62%
$11.47
NIO
-5.75%
$7.04
ADAP
+15.74%
$0.14
WOK
-5.22%
$0.08
AAL
-0.70%
$11.31
RIG
+0.94%
$3.19
IONZ
+5.83%
$4.34
TPIC
-45.91%
$0.12
AXDX
-61.36%
$0.03
MRM
+102.75%
$2.94
QBTS
+1.59%
$26.76
VALE
-1.74%
$10.70
IREN
-9.57%
$41.86
BTG
+1.44%
$4.92
BLMZ
+12.51%
$0.20
QUBT
-2.11%
$20.14
MARA
+0.37%
$16.13
KVUE
+1.54%
$16.42
RIOT
+5.67%
$17.69
KDLY
+7.69%
$1.26
ATCH
-4.25%
$0.79
AAPL
-0.54%
$255.46
SOUN
-2.50%
$15.94
PLTR
-0.86%
$177.57
BITF
-5.22%
$2.54
BBD
+0.91%
$3.30
TLRY
-3.36%
$1.14
WBD
-1.36%
$19.51
AMZN
+0.74%
$219.78
FCX
+1.16%
$35.75
BURU
-10.14%
$0.12
BMNR
+1.87%
$50.50
IXHL
-0.01%
$0.59
ETHD
-6.19%
$3.94
RMBL
+60.50%
$3.21
RXRX
+1.94%
$4.72
SHOT
+12.24%
$0.28
RR
+2.68%
$4.20
GRAB
-2.24%
$6.11
ADD
-25.47%
$0.05
RAYA
-3.15%
$0.04
RIVN
-0.95%
$15.59
SOFI
-0.49%
$27.98
ONDS
-1.16%
$7.66
BULL
+3.55%
$15.16
CVE
+0.39%
$17.77
CLSK
-5.26%
$12.96
SRM
+53.27%
$10.30
ACHR
-0.53%
$9.27
PFE
+0.67%
$23.76
IONQ
-3.09%
$67.28
BB
+6.66%
$4.96
JOBY
+1.57%
$16.11
NOK
-0.42%
$4.66
AMD
-1.12%
$159.46
CRWV
-4.98%
$120.34
CLF
+2.48%
$12.37
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
BTE
+2.43%
$2.52
QS
+1.28%
$12.66
WLGS
-5.57%
$0.04
HIMS
+6.43%
$58.40
AQMS
+48.37%
$7.30
ABEV
0.00%
$2.29
MRVL
-0.76%
$83.17
ETWO
0.00%
$3.30
ORCL
-2.70%
$283.45
HBAN
+0.57%
$17.42
HOOD
-0.70%
$121.78
AG
+4.02%
$12.14
AIIO
-15.63%
$2.04
NWTN
-15.63%
$2.04
SDM
-86.40%
$1.85
T
+0.03%
$28.31
OKLO
-7.21%
$110.53
ITUB
+0.55%
$7.24
MU
+0.28%
$157.27
PCG
+3.67%
$14.97
PR
-0.07%
$13.68
AFMD
-34.94%
$0.18

Charts powered by TradingView


Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.